{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Albertini MR"],"funding":["BLRD VA","NCI NIH HHS","NIH HHS"],"pagination":["307-318"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11444423"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(4)"],"pubmed_abstract":["Canine malignant melanoma provides a clinically relevant, large animal parallel patient population to study the GD2-reactive hu14.18-IL-2 immunocytokine as it is similar to human melanoma and expresses GD2. The objectives of this study were to evaluate safety, radiation fractionation, and identify informative biomarkers of an in-situ tumor vaccine involving local radiation therapy plus intratumoral-immunocytokine in melanoma tumor-bearing dogs. Twelve dogs (six dogs/arm) with locally advanced or metastatic melanoma were randomized to receive a single 8 Gy fraction (arm A) or three 8 Gy fractions over 1 week (arm B) to the primary site and regional lymph nodes (when clinically involved) with the single or last fraction 5 days before intratumoral-immunocytokine at 12 mg/m 2 on 3 consecutive "],"journal":["Melanoma research"],"pubmed_title":["Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma."],"pmcid":["PMC11444423"],"funding_grant_id":["P30 CA008748","I01 BX003916","R35 CA197078","S10 OD023526","P30 CA014520"],"pubmed_authors":["Shiyanbola O","Sondel PM","Kurzman ID","Albertini MR","Schwartz RW","Ranheim EA","Turek M","Vail DM","Eickhoff J","Morris ZS","Ong IM","Newton MA","Hayim R","Zuleger CL"],"additional_accession":[]},"is_claimable":false,"name":"Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.","description":"Canine malignant melanoma provides a clinically relevant, large animal parallel patient population to study the GD2-reactive hu14.18-IL-2 immunocytokine as it is similar to human melanoma and expresses GD2. The objectives of this study were to evaluate safety, radiation fractionation, and identify informative biomarkers of an in-situ tumor vaccine involving local radiation therapy plus intratumoral-immunocytokine in melanoma tumor-bearing dogs. Twelve dogs (six dogs/arm) with locally advanced or metastatic melanoma were randomized to receive a single 8 Gy fraction (arm A) or three 8 Gy fractions over 1 week (arm B) to the primary site and regional lymph nodes (when clinically involved) with the single or last fraction 5 days before intratumoral-immunocytokine at 12 mg/m 2 on 3 consecutive ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-03-18T13:30:05.74Z","creation":"2025-08-18T09:54:15.833Z"},"accession":"S-EPMC11444423","cross_references":{"pubmed":["38768442"],"doi":["10.1097/CMR.0000000000000975","10.1097/cmr.0000000000000975"]}}